Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study.
CONCLUSION: In conclusion, we show that the use of poly-chemotherapy and immunotherapy has disseminated to community practice to a fair extent and survival has increased over time at least in younger patients. Annually increasing conditional survival rates provide clinicians with an adequate and encouraging prognostic measure.
PMID: 30994047 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Neuhauser M, Roetzer T, Oberndorfer S, Kitzwoegerer M, Payer F, Unterluggauer JJ, Haybaeck J, Stockhammer G, Iglseder S, Moser P, Thomé C, Stultschnig M, Wuertz F, Brandner-Kokalj T, Weis S, Bandke D, Pichler J, Hutterer M, Krenosz KJ, Boehm A, Mayrbaeur Tags: Acta Oncol Source Type: research
More News: Austria Health | Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Chemotherapy | Hodgkin's Disease | Immunotherapy | Lymphoma | Methotrexate | Neurology | Non-Hodgkin's Lymphoma | Rituxan | Study